Sanofi is terminating an exclusive license agreement with Maze Therapeutics for the development of a drug candidate to treat Pompe disease because of objections from the U.S. government.   The agreement, announced in May 2023, is for MZE001, a glycogen synthase 1 (GYS1) inhibitor program that has completed Phase 1 and is in development for Pompe Disease, a rare, inherited and often fatal disorder that disables the heart and skeletal muscles.   The Maze partnership was designed to apply Sanof...